Comparative Pharmacology
Head-to-head clinical analysis: FABHALTA versus ZILBRYSQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABHALTA versus ZILBRYSQ.
FABHALTA vs ZILBRYSQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fabhalta (iptacopan) is a complement factor B inhibitor that binds to factor B and prevents the formation of the alternative pathway C3 convertase, thereby inhibiting complement alternative pathway activation.
Zilbrysq (zilucoplan) is a complement component 5 (C5) inhibitor. It binds to C5 with high affinity, preventing its cleavage into C5a and C5b and thereby inhibiting the terminal complement pathway, including the formation of the membrane attack complex (MAC).
200 mg orally twice daily.
Subcutaneous administration of 32 mg three times per week.
None Documented
None Documented
Terminal elimination half-life is approximately 8 hours (range 6-10 hours), supporting twice-daily dosing for sustained complement inhibition.
Terminal elimination half-life is approximately 40 days, supporting a monthly subcutaneous dosing interval.
Primarily renal (approximately 70% as unchanged drug) and biliary/fecal (approximately 30% as metabolites).
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as unchanged drug and metabolites.
Category C
Category C
Complement Inhibitor
Complement Inhibitor